J&J's Tremfya succeeds in late-stage trial for ulcerative colitis

• New phase 3 data on Johnson & Johnson (NYSE:JNJ) Janssen unit's Tremfya (guselkumab) indicate that the biologic is effective as an ulcerative colitis treatment.
• Results from the Quasar induction study showed that 22.6% of those on Tremfya achieved clinical remission at week 12 -- the primary endpoint -- compared to 7.9% of those on placebo.
• At week 12, 49.9% of Tremfya patients achieved symptomatic remission compared to 20.7% of placebo patients. At the same time point, 61.5% of Tremfya patients saw a clinical response compared to 27.9% of placebo patients.
• Tremfya is currently approved for plaque psoriasis and psoriatic arthritis.

More on Tremfya

• J&J analysis: Early Tremfya efficacy in psoriatic arthritis can predict long-term response

• Johnson & Johnson's Tremfya demonstrates long-term benefit in psoriatic arthritis